Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.
Also called NCT07830719
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT07830719
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Germany, Japan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07830719. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-18 (actual); primary completion 2027-08-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- YMI024
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07830719- Content hash
280678c82037bad070dc60215b05c6088cd358774637c93803454fbe00c7b727